| Ad Title: |
A vaccine treatment for AML patients in complete clinical remission |
| Study Title: |
A Phase I/II Study of Active Immunotherapy with GRNVAC1, Autologous Mature Dendritic Cells Tranfected with mRNA Encoding Human Telomerase Reverse Transcriptase (hTERT), in Patients with Acute Myelogenous Leukemia (AML) in Complete Clinical Remission. |
| Protocol Number: |
022007-006 |
| Department(s) involved in the Study: |
Internal Medicine
|
| Purpose of the Study: |
To evaluate the safety and feasibility of immunotherapy with GRNVAC1 in AML patients in complete remission |
| Participant Eligibility: |
18 years of age or older, AML diagnosis first remission or second remission with first remission lasting a minimum of 12 months, have completed at least one consolidation chemotherapy cycle at time of screening, good kidney and liver function. |
| Disease/Condition Under Study: |
AML in first complete remission or second remission with first remission status of least a 12 month duration. |
| Cancer Related Study: |
Yes
|
| Study Drug(s): |
GRNVAC1 (Autologous Mature Dendritic cells transfected with mRNA Encoding H
|
| Study Device(s): |
|
| Study Doctor: |
Dr. Robert Collins |
| Location of Study: |
|
Sites
|
Recruiting at this Site
|
|
Aston Ambulatory Care Center
|
Yes
|
|
UT Southwestern Medical Center, Simmons Cancer Center
|
Yes
|
|
| Contact Phone: |
214_648_5102 |
| Email: |
tracee. rainey@utsouthwestern.Edu |
| Other Information: |
|
| Website Keywords: |
Hematology, Oncology
|
| Medical Keywords: |
AML, cancer, leukemia
|
